Image source: Getty Images.
Investors in CoLucid Pharmaceuticals (NASDAQ: CLCD) should be smiling from ear to ear today. Shares of the clinical-stage biopharmaceutical company shot up 33% yesterday in response to receiving a buyout offer from pharma giant Eli Lilly (NYSE: LLY).